Rhumbline Advisers Buys 504 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Rhumbline Advisers grew its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 0.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 383,113 shares of the biopharmaceutical company’s stock after purchasing an additional 504 shares during the quarter. Rhumbline Advisers owned about 0.25% of TG Therapeutics worth $11,532,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Valeo Financial Advisors LLC increased its stake in TG Therapeutics by 32.4% during the 4th quarter. Valeo Financial Advisors LLC now owns 13,532 shares of the biopharmaceutical company’s stock valued at $407,000 after purchasing an additional 3,309 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 371 shares during the last quarter. New York State Teachers Retirement System boosted its holdings in shares of TG Therapeutics by 1.9% in the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company’s stock worth $1,317,000 after buying an additional 837 shares during the last quarter. Castellan Group purchased a new position in shares of TG Therapeutics in the fourth quarter worth approximately $8,539,000. Finally, Van ECK Associates Corp bought a new stake in TG Therapeutics during the 4th quarter worth approximately $4,219,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $30.88 on Monday. The business’s 50 day moving average price is $31.07 and its 200 day moving average price is $27.84. The firm has a market cap of $4.81 billion, a P/E ratio of -308.77 and a beta of 2.26. TG Therapeutics, Inc. has a 52 week low of $12.90 and a 52 week high of $36.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares in the company, valued at $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

TGTX has been the topic of several recent analyst reports. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 31st. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.